-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Upgrades Sutro Biopharma to Market Outperform, Announces $23 Price Target

Benzinga·01/20/2026 10:25:08
Listen to the news
Citizens analyst Reni Benjamin upgrades Sutro Biopharma (NASDAQ:STRO) from Market Perform to Market Outperform and announces $23 price target.